STOCK TITAN

Lixte Biotechnology (LIXTW) director Form 3 shows no share ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Lixte Biotechnology Holdings, Inc. director Guy Primus filed an initial insider ownership report on Form 3 as of 09/01/2025. The filing states that no securities of the company are beneficially owned, and both the non-derivative and derivative securities tables are blank.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Primus Guy Warren

(Last) (First) (Middle)
680 E. COLORADO BOULEVARD, SUITE 180

(Street)
PASADENA CA 91101

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2025
3. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Guy Primus 09/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the LIXTW Form 3 filed by Guy Primus report?

The Form 3 reports that no securities are beneficially owned. Director Guy Primus filed an initial ownership statement for Lixte Biotechnology Holdings, Inc., indicating that he does not beneficially own any non-derivative or derivative securities of the company as of September 1, 2025.

Who is the reporting person on the LIXTW Form 3?

The reporting person is Guy Warren Primus. He is identified as a director of Lixte Biotechnology Holdings, Inc. on the Form 3 and confirms his status by signing the filing, which reports his insider relationship and current beneficial ownership position with the company.

Does the LIXTW Form 3 show any stock or options owned by the director?

No, the Form 3 shows no stock or options owned. Both Table I for non-derivative securities and Table II for derivative securities are effectively empty, and the explanation of responses clearly states that no securities are beneficially owned by the reporting director.

What is the event date disclosed on the LIXTW Form 3?

The event date disclosed is September 1, 2025. This date is listed as the date of the event requiring the Form 3 statement, which typically reflects when the person became a reporting insider, such as assuming the role of director at the company.

Is the LIXTW Form 3 filed by more than one reporting person?

No, it is filed by one reporting person. The filing box indicates that the Form 3 is submitted by a single reporting person, namely director Guy Warren Primus, with no joint or group filing status reported for this ownership statement.

What type of relationship to Lixte does the LIXTW Form 3 indicate?

The filing identifies the reporting person as a director. The relationship section has the “Director” box checked, while the boxes for 10% owner, officer, and other roles are not selected, clarifying that his insider status is solely in the capacity of board director.
Lixte Biotechnology Hldgs Inc

NASDAQ:LIXTW

View LIXTW Stock Overview

LIXTW Rankings

LIXTW Latest News

LIXTW Latest SEC Filings

LIXTW Stock Data

1.50M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOCA RATON